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ess under CC BY-NC-Abstract Arsenic trioxide (ATO) has been identiﬁed as an effective treatment for acute promyelocytic
leukemia (APL) but is much less effective against solid tumors such as hepatocellular carcinoma (HCC). In the
search for ways to enhance its therapeutic efﬁcacy against solid tumors, we have examined its use in combination
with a novel derivative of β-elemene, N-(β-elemene-13-yl)tryptophan methyl ester (ETME). Here we report the
effects of the combination on cell viability, apoptosis, the cell cycle and mitochondria membrane potential
(MMP) in HCC SMMC-7721 cells. We found that the two compounds acted synergistically to enhance
antiproliferative activity and apoptosis. The combination also decreased the MMP, down-regulated Bcl-2 and
pro-proteins of the caspase family, and up-regulated Bax and BID, all of which were reversed by the p53
inhibitor, piﬁthrin-α. In addition, the combination induced cell cycle arrest at the G2/M phase and reduced tumor
volume and weight in an xenograft model of nude mice. Overall, the results suggest that ETME in combination
with ATO may be useful in the treatment of HCC patients particularly those unresponsive to ATO alone.
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ETME, a novel β-elemene derivative 4251. Introduction
On a worldwide basis, hepatocellular carcinoma (HCC) is the sixth
most common cancer in terms of incidence but the third most
common in causing death. Therefore there is a distinct need for
novel chemotherapeutic agents with greater efﬁcacy against HCC1.
Arsenic trioxide (ATO) has been shown to successfully treat acute
promyelocytic leukemia (APL) but is much less effective against
solid tumors such as HCC. In fact in a phase II trial, ATO alone
was inefﬁcient in the treatment of HCC, suggesting that strategies
to enhance and expand its therapeutic efﬁcacy are needed2.
Although β-elemene (Fig. 1A) has been approved for the
treatment of advanced cancer in China, its clinical application has
been limited by poor antiproliferative efﬁcacy, low water solubility
and instability. This has led to the search for new
β-elemene derivatives (Fig. 1A) with improved physicochemical
and pharmacokinetic properties and enhanced antiproliferative
effects. We previously reported that the novel β-elemene derivative,
N-(β-elemene-13-yl)tryptophan methyl ester (ETME, Fig. 1B),
exerts potent antiproliferative activity against human leukemia cells
both alone and in combination with ATO3,4. However, the efﬁcacy
of ETME alone and in combination with ATO in treating HCC is
unknown. In this study, we show that the two compounds act
synergistically to induce apoptosis and cell cycle arrest at the G2/M
phase in HCC SMMC-7721 cells via a p53-dependent pathway and
reduce tumor volume and weight in vivo.2. Materials and methods
2.1. Reagents
MTT was obtained from the Ameresco Co., Inc. (Ameresco, CA,
USA). Ethidium bromide (EB), acridine orange (AO), propidium
iodide (PI), rhodamine 123 (Rh123), piﬁthrin-α (PFT-α), caspase
inhibitor (Z-VAD-FMK), the annexin V-FITC apoptosis detection
kit, the BCA protein determination kit and speciﬁc secondary
antibodies were purchased from Beyotime Biotech. (Haimen,
Jiangsu, China). Hoechst 33342 was obtained from Sigma (St.
Louis, MO, USA). Antibodies to pro-caspase-3, -8 and -9, Bcl-2,Figure 1 Chemical structures of (A) β-elemene and (B) N-(β-
elemene-13-yl)tryptophan methyl ester (ETME).Bax, BID, p53, p27, cyclinD1, cyclinB1 and CDK1 were
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA).
2.2. Cell culture
Human HCC SMMC-7721 cells and HepG2 cells were incubated
in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 U/mL penicillin and 100 μg/mL streptomycin. The
cultures were maintained at 37 1C in an incubator under 5% CO2.
2.3. Cell proliferative evaluation
Cells were seeded in 96-well plates at a density of 5 103 cells/well
and incubated for 24 h before adding ETME, ATO or their
combination. After incubation for 48 h, 50 mL MTT reagent
(1 mg/mL) was added and the plates incubated at 37 1C for a
further 4 h in a humidiﬁed incubator under 5% CO2. Supernatants
were removed from the wells, the crystalline product dissolved in
100 mL DMSO and the plates incubated at room temperature for
10 min. The absorbance was then measured with a microplate reader
(Bio-Rad) at a wavelength of 570 nm. The combination index (CI)
was calculated as EAþB/(EAþ(1EA)EB), where EA, EB and
EAþB are the inhibition ratios of A, B and (AþB) respectively.
Antagonism, enhancement and synergism are indicated by
CIo0.85, 0.85rCIr1.15 and CI41.15, respectively5.
2.4. Cellular apoptotic evaluation
Based on CI values, we selected concentrations of ETME and
ATO of 20 and 5 μmol/L respectively and SMMC-7721 cells for
further study. Cell apoptosis was evaluated using the AnnexinV-
FITC apoptosis detection kit. Brieﬂy, the cells were seeded in 6-
well plates and exposed to the indicated concentrations of ETME,
ATO and their combination. After treatment for 48 h, cells were
harvested, stained according to the manufacturer's protocol and
analyzed using HCS. Cell apoptosis was also detected using AO
and EB staining. In brief, cells treated with ETME, ATO or the
combination for 48 h were incubated with AO (10 μg/mL) and EB
(10 μg/mL) for 30 min in dark and then analyzed using HCS. EB-
positive cells with nuclear shrinkage, blabbing and apoptotic
bodies were counted as apoptotic cells and the apoptotic ratio
was calculated after observing 300 cells. For caspase inhibitor
analysis, cells were pretreated for 2 h with 50 μmol/L Z-VAD-
FMK 1.
2.5. Cell cycle analysis
Cells were seeded in 25 cm2 ﬂasks and pre-incubated in
RPMI1640 medium supplemented with 0.2% fetal calf serum for
24 h to induce cell cycle synchronization. The synchronous cells
were then treated with ETME, ATO or the combination and
incubated for 48 h. Cells were washed twice with ice-cold
phosphate buffered saline (PBS), ﬁxed, and permeabilized with
ice-cold 70% ethanol at 20 1C overnight. Cells were subse-
quently treated with 50 mg/mL RNase A at room temperature for
30 min, washed with ice-cold PBS and ﬁnally stained with 50 mg/mL
PI in dark at 4 1C for 30 min. The distribution of cell cycle phases
with different DNA contents was analyzed using HCS on the basis of
acquiring 10,000 events for each sample1.
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After treatment, SMMC-7721 cells were harvested and washed
with PBS. Total cellular protein was isolated using the protein
extraction buffer and determined using the BCS protein assay kit.
Cell lysates in 5 SDS sample buffer were boiled for 5 min after
which equal amounts of protein (50 μg/lane) were fractionated using
8% or 12% SDS-PAGE and transferred to PVDF membranes. After
blocking with PBST containing 5% dried skimmed milk, the
membranes were cultured with primary antibodies at 4 1C overnight.
After washing with PBS, the blots were incubated with the
corresponding peroxidase-conjugated goat anti-mouse or anti-
rabbit secondary antibody followed by detection using ECL plus
reagents1.Figure 2 (A) The antiproliferative activity of ETME in HepG2 cells and
activity of ETME, ATO and their combination in HepG2 cells after 48 h
combination in SMMC-7721 cells after 48 h treatment. Data are expressed
Figure 3 Effect of the combination of ETME (20 μmol/L) and ATO (5 μ
loading control. (A) Top, original data, Bottom, bar chart showing stat
ﬂuorescence intensity of EB after treatment; (D) protein expression detect
n¼3. *Po0.05, **Po0.01 vs control.2.7. Animal treatment
A group of male BALB/c nude mice (n¼40) was purchased from
the Animal Center, Vital River (Beijing, China). The mice were
provided with food and water ad libitum on a 12:12 day/night
cycle maintained at around 26 1C. Suspensions of 2 106 SMMC-
7721 cells were injected subcutaneously into the armpits of mice
and tumor growth monitored every 3 days. When the average
tumor volume reached 100 mm3, the tumor-bearing mice were
randomly divided into four groups and treated with either saline,
50 mg/kg/d ETME, 3 mg/kg/d ATO or the combination for 2
weeks. The volume of the tumor was calculated from the formula
V¼1/2 (AB2), where A is the longest diameter and B the
perpendicular diameter measured using calipers. At the end ofSMMC-7721 cells tested after 48 h treatment; (B) the anti-proliferative
treatment; (C) the anti-proliferative activity of ETME, ATO and their
as mean7SD, n¼3.
mol/L) on apoptosis of SMMC-7721 cells after 48 h using β-actin as
istical results; (B) ﬂuorescence intensity of AO after treatment; (C)
ed by Western blot after treatment. Data are expressed as mean7SD,
ETME, a novel β-elemene derivative 427treatment, mice were sacriﬁced and the tumors excised for
analysis6.2.8. Data analysis
All data are presented as mean7SD and analyzed using Student's
t-test or analysis of variance (ANOVA) followed by a q test.3. Results
3.1. Inhibition of cell growth
The results of cell growth inhibition studies show that ETME exerts
potent antiproliferative effects on both SMMC-7721 and HepG2 cells
in a dose-dependent manner with SMMC-7721 cells being more
sensitive (Fig. 2A). In terms of the effect of the combination of ETME
and ATO, we found that treatment of SMMC-7721 cells with 20 μmol/L
ETME and 5 μmol/L ATO for 48 h gave the maximum CI value of
7.29 (Fig. 2B and C). We therefore used this system for further studies.Figure 4 Synergistic effect of the combination of ETME (20 μmol/L) an
SMMC-7721 cells after 48 hs. (A) Apoptosis detected by AO/EB staining
tumor volume (left) and weight (right) of SMMC-7721 cell xenografts in
14 d. Data are expressed as mean7SD, n¼10. **Po0.01 vs control.3.2. SMMC-7721 cell apoptosis
Using Annexin-FITC staining, treatment with ETME and ATO
alone caused no signiﬁcant differences in the rate of apoptosis
compared with the control group (P40.05) but treatment with the
combination led to a signiﬁcantly greater rate of apoptosis
(Po0.05) compared with the control group (Fig. 3A). Further-
more, using AO/EB staining (Fig. 4A), treatment with the
combination caused signiﬁcant increases in AO (Fig. 3B) and
EB (Fig. 3C) ﬂuorescence compared with the control group
(Po0.05). These results suggest the synergistic antiproliferative
effect is at least partly mediated through apoptosis.
In order to further investigate the mechanism of the synergistic
effect, Western blot analysis was used to determine the protein
levels of apoptotic related proteins. The results show that the levels
of p53, Bax and BID proteins were not signiﬁcantly changed after
treatment with ETME alone (Fig. 3D) but treatment with the
combination promoted the activation of caspase-3, caspase-8 and
caspase-9, up-regulated the protein levels of p53, Bax and BID and
down-regulated the protein expression of Bcl-2 compared with the
control (untreated) group (Fig. 3D).d ATO (5 μmol/L) on apoptosis, the cell cycle and tumor growth of
(100 ); (B) cell cycle progress detected by PI staining (100 ); (C)
nude mice after treatment with ETME, ATO or their combination for
Figure 5 Effect of pre-treatment with PFT-α and Z-VAD-FMK on apoptosis of SMMC-7721 cells caused by treatment with ETME (20 μmol/L),
ATO (5 μmol/L) or their combination for 48 h. (A) Effect of pre-treatment with PFT-α (10 μg/mL) for 1 h on apoptosis; (B) effect of pre-treatment
with PFT-α (10 μg/mL) for 1 h on protein expression detected by Western blot; (C) effect of pre-treatment with Z-VAD-FMK (10 μg/mL) for 1 h
on apoptosis; (D) effect of pre-treatment with Z-VAD-FMK (10 μg/mL) for 1 h on protein expression detected by Western blot. Data are expressed
as mean7SD, n¼3. *Po0.05, **Po0.01 vs control.
Figure 6 ETME synergized with As2O3 to induce cell cycle arrest in SMMC-7721 cells. (A) The cell cycle progress of SMMC-7721 cells was
detected after treatment with ETME, As2O3 or their combination for 48 h. Data are expressed as mean7SD, n¼3. *Po0.05, **Po0.01 vs control.
(B) The protein expression of SMMC-7721 cells was detected after treatment with ETME, As2O3 or their combination for 48 h. β-actin is used as a
loading control.
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Activation of p53 can induce apoptosis and bring about cell cycle
arrest and senescence7. To determine the role of p53 in the
synergistic apoptotic effect of ETME and ATO, we evaluated the
effect of the p53-speciﬁc inhibitor, PFT-α. As shown in Fig. 5A,
pre-treatment of cells with PFT-α markedly reduced apoptosis
compared with the untreated group. Furthermore, Western blot
analysis showed that the impact of the two agents either alone or in
combination on Bcl-2, Bax, caspase-3, caspase-8 and caspase-9
was reversed by PFT-α pre-treatment (Fig. 5B). In addition, pre-
treatment of cells with the caspase inhibitor, Z-VAD-FMK,
attenuated apoptosis (Fig. 5C), caspase activation and Bcl-2down-regulation (Fig. 5D). These results suggest that the apoptotic
effect of the combination of ETME and ATO is due to the
activation of the p53 signaling pathway and members of the
caspase family.3.4. Effect on cell cycle progression
p53 is also linked with control of cell cycle progression7,8. After
treatment with ETME, ATO or their combination for 48 h, the
number of cells in the G2/M phase was much greater than in the
untreated group and the highest in the group treated with the
combination (Figs. 6A and 4B). Furthermore, Western blot
ETME, a novel β-elemene derivative 429analysis showed that the levels of cell cycle-related proteins such
as p27, cyclin D1, cyclin B1 and CDK1 were much increased
compared with the untreated group and could be partly attenuated
by PFT-α (Fig. 6B).
3.5. Tumor growth in nude mice
After treatment with ETME or ATO alone, tumor volume and
weight in the xenograft model degraded but not signiﬁcantly
compared with the control group (P40.05). In contrast, treatment
with the combination signiﬁcantly reduced (Po0.05) the tumor
volume and weight compared with the control group (Fig. 4C).4. Discussion
β-Elemene displays potent antitumor activity both in vitro and
in vivo and has been identiﬁed as a complementary drug for cancer
treatment in China9–13. Previous research has revealed that the
novel derivative of β-elemene, ETME, has higher water-solubility
and exhibits potent antiproliferative activity against human leuke-
mia cells3. In the present study, we found that ETME displayed
similar activity against SMMC-7721 and HepG2 cells and, in
combination with ATO, produced a greater antiproliferative effect
than either agent alone both in vitro and in vivo. This synergistic
effect was previously observed in human leukemia cells and
suggests the combination may be useful in the treatment of HCC
patients unresponsive to ATO alone.
Previous research in our laboratory data demonstrated that
ETME and other β-elemene derivatives such as DX1, alone or in
combination with ATO, could induce apoptosis in human leuke-
mia cells3,4. We have now shown this to also be the case in
SMMC-7721 cells where the apoptotic effect was accompanied by
up-regulation of p53, BID and Bax, down-regulation of Bcl-2 and
activation of members of the caspase family. The latter changes are
in contrast to the effects of the combination on human leukemia
cells where apoptosis was accompanied by the activation of
caspase-3 but no changes in the expression of Bcl-2 and Bax3.
To detect whether p53 is the key mediator of apoptosis
produced by the combination, SMMC-7721 cells were pretreated
with the p53 inhibitor PFT-α. The results indicate that PFT-α not
only reversed the synergistic apoptotic effect of the combination of
ETME and ATO but also blocked the accompanying changes in
p53, BID, Bax, Bcl-2 and members of the caspase family. This
clearly indicates that p53 plays an important role in the synergistic
apoptotic effect. In addition, given that the caspase inhibitor, Z-
VAD-FMK, also attenuated apoptosis, it appears that members of
the caspase family also play a key role.
Since p53 also regulates the cell cycle14,15, we examined the
effects of treatment with ETME and ATO on it. The results show
that the cell cycle was arrested at the G2/M phase and that the
expression of p27, cyclin D1, cyclin B1 and CDK1 was induced
but not in the presence of PFT-α. This suggests that p53 exerts a
vital role in the ability of the combination of ETME and ATO to
induce cell cycle arrest.5. Conclusions
The present study shows that the combination of ETME and ATO
induces apoptosis and cell cycle arrest of hepatocellular carcinomacells in a p53-dependent manner and reduced tumor volume and
weight in an xenograft model of nude mice. The results suggest
that the combination may be useful in the treatment of patients
with HCC.Acknowledgment
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